ECSP22020678A - ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES - Google Patents

ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES

Info

Publication number
ECSP22020678A
ECSP22020678A ECSENADI202220678A ECDI202220678A ECSP22020678A EC SP22020678 A ECSP22020678 A EC SP22020678A EC SENADI202220678 A ECSENADI202220678 A EC SENADI202220678A EC DI202220678 A ECDI202220678 A EC DI202220678A EC SP22020678 A ECSP22020678 A EC SP22020678A
Authority
EC
Ecuador
Prior art keywords
nrp1a
antibodies
eye diseases
treat eye
treat
Prior art date
Application number
ECSENADI202220678A
Other languages
Spanish (es)
Inventor
Leo Thomas
Sarah Low
Juergen Prestle
Fei Han
Yining Huang
Nina Zippel
Pankaj Gupta
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2020/076685 external-priority patent/WO2021058636A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22020678A publication Critical patent/ECSP22020678A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre el domino A de Neuropilina-1 (Nrp1A). Más específicamente, se divulgan anticuerpos anti-Nrp1A y métodos de uso para el tratamiento de varias enfermedades o trastornos.The present invention relates to antibodies and fragments of these that act on the A domain of Neuropilin-1 (Nrp1A). More specifically, anti-Nrp1A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.

ECSENADI202220678A 2019-09-24 2022-03-21 ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES ECSP22020678A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19199099 2019-09-24
PCT/EP2020/076685 WO2021058636A1 (en) 2019-09-24 2020-09-24 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
ECSP22020678A true ECSP22020678A (en) 2022-04-29

Family

ID=68066567

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202220678A ECSP22020678A (en) 2019-09-24 2022-03-21 ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES

Country Status (2)

Country Link
AR (1) AR120038A1 (en)
EC (1) ECSP22020678A (en)

Also Published As

Publication number Publication date
AR120038A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2023015185A (en) PROTEIN DEGRADERS AND USES THEREOF.
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
CL2020000483A1 (en) New uses of piperidinyl-indole derivatives.
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
ECSP19015192A (en) COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
CL2019002368A1 (en) Compositions and methods for the treatment of cancer.
CO2021014768A2 (en) Anti-sema3a antibodies and their uses to treat eye diseases
CL2021000163A1 (en) Anti-htra1 antibodies and methods of using them. (application divisional 201801139)
MX2017013562A (en) MICROBIOMA REGULATORS AND RELATED USES OF THE SAME.
CO2023006684A2 (en) Antibodies against sars-cov-2 and their uses
CL2019002251A1 (en) Antibodies against tryptase, compositions of these and uses of these.
DOP2018000219A (en) ANTI-FACTOR ANTIBODIES BB OF THE COMPLEMENT AND USES OF THESE
CL2020003008A1 (en) Selective treg stimulator rur20kd-il-2 and related compositions
MX2021002301A (en) BIOCONJUGATES OF ANTIBODY-FOLIATE ANTI-CD3 AND THEIR USES.
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
CO2023000557A2 (en) Antibodies and methods for treating claudin-associated diseases
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
DOP2024000117A (en) ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES IN TREATING OPHTHALMIC OR OCULAR DISEASES
MX2021006865A (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND THEIR USES.
MX2021002652A (en) USE OF CASEIN-KINASE 1 INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES.
CL2021000930A1 (en) Novel Pyridazines
MX2021011334A (en) Antibodies having specificity for btn2 and uses thereof.
CO2022003324A2 (en) Anti-nrp1a antibodies and their uses to treat eye diseases
ECSP22020678A (en) ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES
MX2021009767A (en) FMCR UNION MOLECULES AND USES THEREOF.